Department of Gastrointestinal Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
GI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Cancer Med. 2024 Nov;13(21):e70378. doi: 10.1002/cam4.70378.
Colorectal cancer (CRC) is associated with high incidence and mortality rates globally. The presence of intraperitoneal free cancer cells (IFCCs) is recognized as an independent prognostic factor for CRC patients. However, a clinical gold standard for IFCCs detection is lacking. The GILUPI CellCollector has demonstrated high sensitivity and specificity in detecting free cancer cells, yet its application for CRC IFCCs detection remains unreported.
We selected CRC and normal cell lines to evaluate the CellCollector's ability to detect tumor cells. A total of 70 CRC patients and 17 patients with benign disease undergoing laparoscopic procedures were investigated. Peritoneal lavage fluid was collected pre- and post-operation, and both real-time PCR (CEA mRNA) and CellCollector detection were performed. We compared the sensitivity and specificity of these two methods.
CellCollector can distinguish well between CRC and normal cells in cell line experiments. CellCollector detects IFCCs better than real-time PCR (CEA) in CRC patients in different TNM Stages. The sensitivity of CellCollector was higher than that of real-time PCR (84.6% vs. 48.4%), and the specificity of CellCollector was also higher than real-time PCR (79.1% vs. 60.4%). There was no significant difference in the results of IFCCs detected by CellCollector before and after total mesorectal excision (TME) or complete mesocolic excision (CME) radical colorectomy (p > 0.05), but there was a significant difference in real-time PCR detection (p < 0.05).
The CellCollector demonstrates superior sensitivity and specificity compared to real-time PCR for detecting IFCCs in CRC patients, suggesting its potential as a clinical tool for IFCCs detection.
ClinicalTrials.gov identifier: NCT01978444.
结直肠癌（CRC）在全球范围内具有较高的发病率和死亡率。腹腔内游离癌细胞（IFCCs）的存在被认为是 CRC 患者的独立预后因素。然而，目前缺乏检测 IFCCs 的临床金标准。GILUPI CellCollector 在检测游离癌细胞方面具有较高的灵敏度和特异性，但尚未有其用于 CRC IFCCs 检测的报道。
我们选择 CRC 和正常细胞系来评估 CellCollector 检测肿瘤细胞的能力。共纳入 70 例 CRC 患者和 17 例接受腹腔镜手术的良性疾病患者。在术前和术后采集腹腔灌洗液，同时进行实时 PCR（CEA mRNA）和 CellCollector 检测。我们比较了这两种方法的灵敏度和特异性。
在细胞系实验中，CellCollector 能够很好地区分 CRC 细胞和正常细胞。在不同 TNM 分期的 CRC 患者中，CellCollector 检测 IFCCs 的灵敏度优于实时 PCR（CEA）（84.6% vs. 48.4%），特异性也优于实时 PCR（79.1% vs. 60.4%）。在 TME 或 CME 根治性结肠切除术前、后，CellCollector 检测 IFCCs 的结果无显著差异（p＞0.05），但实时 PCR 检测结果有显著差异（p＜0.05）。
与实时 PCR 相比，CellCollector 检测 CRC 患者 IFCCs 的灵敏度和特异性更高，提示其作为 IFCCs 检测的临床工具具有潜力。
ClinicalTrials.gov 标识符：NCT01978444。
